Overview

Eyenovia aims to achieve clinical microdosing of next-generation formulations of well-established ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments.

Leadership

Executive Team
Sean_Ianchulev_2

Sean Ianchulev, MD

CEO and President
Tsontcho Ianchulev, MD, MPH has been serving as our Chief Executive Officer and Chief Medical Officer and a member of our Board of Directors since March 2014. From 2009 to 2016, he was the Chief Medical Officer and the head of technology and business development for Transcend Medical, Inc. (acquired by Novartis International AG/Alcon, Inc. (NYSE: NVS)). Prior to that, while at Genentech, Inc. (NASDAQ: DNA, before going private in 2009), Dr. Ianchulev headed the ophthalmology research group and directed the development and the FDA approval of Lucentis. Dr. Ianchulev currently serves as a director of the ASCRS Foundation and on the advisory board of Alcon. He was formerly chairman of the board of directors of ianTECH from 2014 until its acquisition by Carl Zeiss Meditec in 2019. Dr. Ianchulev received his B.S. from the University of Rochester. He received both his M.D. and an M.P.H. from Harvard University and completed his specialty training at the Doheny Eye Institute. Currently, Dr. Ianchulev serves as a professor in the New York Eye and Ear Infirmary of Mount Sinai.
ginger_update4

Ginger Clasby

Clinical Operations
Jennifer “Ginger” Clasby has been serving as our Vice President, Clinical Operations since September 2017. From 2009 to September 2017, she served as Vice President, Clinical & Regulatory Affairs/Quality Assurance at Transcend Medical. In that position, she was responsible for overseeing clinical operations and regulatory processes for the company’s clinical trials in the United States, Europe and Latin America, as well as worldwide regulatory affairs, quality assurance and compliance activities. She was also a pivotal executive with Promedica International, a contract research organization, from 1994 to 2009. Prior to that, Clasby worked with ophthalmic device companies American Medical Optics and Optical Radiation Corporation in various roles for approximately 14 years in the areas of clinical affairs, manufacturing operations, marketing and sales. She serves on the University of California-Irvine Extension Life Science Advisory Committee. She holds an M.S. degree in Industrial Engineering from Arizona State University and B.S. degrees in mathematics and physics from Guilford College.
Luke_Clauson

Luke Clauson

R&D, Engineering
Luke Clauson has been serving as our Vice President, Research & Development and Manufacturing since August 2017. He founded a medical device-focused engineering development company, Innovative Drive Corporation, that has helped businesses of all sizes conceptualize and bring dozens of products to market, including several in ophthalmology, in 2004 and has been serving as its President since then. Mr. Clauson has been the President and a director of Inspire products, Inc. since 2012 and also serves on the board of directors of Mimic Motion, Inc. From 2016 until 2018, he was Chief Operating Officer of ianTECH. From 2009 to 2016, Mr. Clauson was Vice President, Research & Development and Operations at Transcend Medical. He started his engineering career at Cardica, Inc. (now Dex Liquidating Co.), where he ultimately directed product development for the core anastomotic business. Mr. Clauson has extensive experience in designing, validating, achieving regulatory approval and scaling for commercialization with multiple products. He holds a B.Sc. in mechanical engineering from the University of California, Davis.
John Galdofo

John Gandolfo

Chief Financial Officer
John Gandolfo has been serving as our Chief Financial Officer and Secretary since December 2017. Mr. Gandolfo has approximately 30 years of experience as a chief financial officer of multiple rapidly growing private and publicly held companies with a primary focus in the life sciences, healthcare and medical device areas. Mr. Gandolfo has had direct responsibility over capital raising, including five public offerings, financial management, mergers and acquisition transactions and SEC reporting throughout his professional career. Prior to joining Eyenovia, Mr. Gandolfo was Chief Financial Officer of Xtant Medical Holdings, Inc. from July 2010 through September 2017. Prior to joining Xtant, he served as the Chief Financial Officer for Progenitor Cell Therapy LLC, a manufacturer of stem cell therapies, from January 2009 to June 2010. Prior to joining Progenitor, Mr. Gandolfo served as the Chief Financial Officer of Power Medical Interventions, Inc. (acquired by Covidien plc, which was in turn acquired by Medtronic plc), a publicly held developer and manufacturer of computerized surgical stapling and cutter systems, from January 2007 to January 2009. Prior to joining Power Medical Interventions, Mr. Gandolfo was the Chief Financial Officer of Bioject Medical Technologies, Inc. (NASDAQ: BJCT), a supplier of needle-free drug delivery systems to the pharmaceutical and biotechnology industries, from September 2001 to May 2006, and served on the Bioject’s board of directors from September 2006 through May 2007. Prior to joining Bioject, Mr. Gandolfo was the Chief Financial Officer of Capital Access Network, Inc., a privately held specialty finance company, from 2000 through September 2001, and Xceed, Inc. (OTC: EXDW), an Internet consulting firm, from 1999 to 2000. From 1994 to 1999, Mr. Gandolfo was Chief Financial Officer and Chief Operating Officer of Impath, Inc., a then publicly held, cancer-focused healthcare information company. From 1987 through 1994, he was Chief Financial Officer of Medical Resources, Inc., a then publicly held manager of diagnostic imaging centers throughout the United States. Mr. Gandolfo received his B.A. in business administration from Rutgers University. He is a certified public accountant (inactive status) who began his professional career at Price Waterhouse.
Lee Kram, MD_3

Lee Kramm, MD

Regulatory
Dr. Lee Kramm is a board certified Ophthalmologist with a Masters' degree in Biomedical Engineering. He earned his graduate degree from the Tulane University School of Engineering and his medical degree from the University of Miami School of Medicine. Following medical school he received general and surgical training in Ophthalmology from the Rocky Mountain Lions Eye Institute at the University of Colorado in Denver. Dr. Kramm served for five years as a medical officer and scientific reviewer in the Division of Ophthalmic,
mikeRowe

Michael Rowe

VP of Commercial
Mr. Rowe brings his extensive experience in ophthalmic drug and device marketing and development to our mission of “Making it PossibleTM.” Mr. Rowe had been serving as our Vice President, Marketing since July 2018. In October 2019, Mr. Rowe assumed additional duties and his title was changed to VP, Commercial. June 2018, Mr. Rowe was head of Global Strategic Marketing, Ophthalmology at Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), where he was responsible for the United States and international commercialization, planning and execution for Rhopressa®, for the lowering of elevated IOP in patients with open-angle glaucoma or ocular hypertension. Previously, he spent 12 years at Allergan plc in various roles supporting corporate strategic initiatives as well as strategic planning for the company’s worldwide glaucoma franchise, including the development of bimatoprost SR and the global launch of Ganfort® UD. Mr. Rowe also has held senior marketing roles at Bayer Healthcare Pharmaceuticals Inc., Women First Healthcare, Inc. and Pfizer Inc (NYSE: PFE). Mr. Rowe holds an M.Sc. in Human Factors/Experimental Psychology from Rensselaer Polytechnic Institute and a B.A. in Psychology from the State University of New York at Stony Brook.
Board of Directors
Sean_Ianchulev_2

Sean Ianchulev, MD

CEO and President
Tsontcho Ianchulev, MD, MPH has been serving as our Chief Executive Officer and Chief Medical Officer and a member of our Board of Directors since March 2014. From 2009 to 2016, he was the Chief Medical Officer and the head of technology and business development for Transcend Medical, Inc. (acquired by Novartis International AG/Alcon, Inc. (NYSE: NVS)). Prior to that, while at Genentech, Inc. (NASDAQ: DNA, before going private in 2009), Dr. Ianchulev headed the ophthalmology research group and directed the development and the FDA approval of Lucentis. Dr. Ianchulev currently serves as a director of the ASCRS Foundation and on the advisory board of Alcon. He was formerly chairman of the board of directors of ianTECH from 2014 until its acquisition by Carl Zeiss Meditec in 2019. Dr. Ianchulev received his B.S. from the University of Rochester. He received both his M.D. and an M.P.H. from Harvard University and completed his specialty training at the Doheny Eye Institute. Currently, Dr. Ianchulev serves as a professor in the New York Eye and Ear Infirmary of Mount Sinai.
FredV3

Fred Eshelman, PHD

Chairman of the board
Dr. Eshelman has been a member of our Board of Directors since December 2014. He has more than 35 years of strategic development, executive, operational and financial leadership experience in the pharmaceutical and healthcare industries. Dr. Eshelman was the founder of Pharmaceutical Product Development, Inc. (NASDAQ: PPDI, before going private in 2011) and founding chairman of Furiex Pharmaceuticals, Inc. (NASDAQ: FURX, acquired by Actavis plc (NYSE: ACT)) from October 2009 to July 2014. Since April 2017, Dr. Eshelman has been serving as the chief executive officer of Innocrin Pharmaceuticals, Inc. Since September 2015, he has been serving as the executive chairman of The Medicines Company, Inc. (NASDAQ: MDCO). In May 2014, Dr. Eshelman founded Eshelman Ventures, LLC, an investment company focused on healthcare companies. From July 2009 to December 2011, he served as executive chairman of Pharmaceutical Product Development. He also served as chief executive officer of Pharmaceutical Product Development from July 1990 to July 2009 and as vice chairman of its board of directors from July 1993 to July 2009. Dr. Eshelman currently serves on the board of directors of Bausch Health Companies Inc. (NASDAQ: BHC, f/k/a Valeant Pharmaceuticals International, Inc.) and G1 Therapeutics, Inc. (NASDAQ: GTHX). Dr. Eshelman received a B.S. in pharmacy from UNC Chapel Hill and a Pharm.D. from the University of Cincinnati, and he completed an OPM program at Harvard University. Dr. Eshelman also received an honorary Doctor of Science from UNC Chapel Hill. We believe that Dr. Eshelman’s experience in drug discovery and development of pharmaceutical products and in strategic planning at a variety of biopharmaceutical companies is of considerable importance and is valuable to our Company and qualifies him to serve as one of our directors.
CurtV3

Curt Labelle, MD

Director
Dr. LaBelle has been a member of our Board of Directors since December 2014. Since July 2015, he has been the managing partner at the Global Health Investment Advisors, LLC and, prior to that, was a managing director at Tullis Health Investors Inc. from 2008 to 2015. From April 2011 to May 2015, Dr. LaBelle served as a member of the board of directors of Exagen Diagnostics, Inc., a commercial stage autoimmune rheumatic disease diagnostics company, and was chairman from December 2011 to May 2015. Dr. LaBelle served as chairman of the board of SafeOp Surgical, Inc., a medical device and technology company acquired by Alphatec Holdings, Inc. (NASDAQ: ATEC), from 2011 to 2015, and Impulse Monitoring, Inc., a neuromonitoring company, from 2008 to 2011 when the company was acquired by NuVasive, Inc. (NASDAQ: NUVA). From 2006 to 2008, Dr. LaBelle served as a member of the board of directors of Sirion Therapeutics, Inc., a company that developed Durezol for ophthalmic post-operative inflammation (acquired by Alcon, Inc.), Zirgan for ocular herpetic keratitis (acquired by Bausch & Lomb Holdings, Inc.), as well as a development program for a topical vancomycin for serious eye infections (acquired by Perrigo Company plc (NYSE: PRGO)). He was also a member of the board of directors of KAI Pharmaceuticals, Inc., a pharmaceutical company developing drugs for patients with chronic kidney disease, since May 2006 until the company was acquired by Amgen Inc. (NASDAQ: AMGN) in July 2012, and TransMolecular, Inc., a neuroscience biotechnology company developing products to treat central nervous system disorders (acquired by Morphotek, Inc.). He has also served in board or other advisory capacities with Alydia Health, Inc., Atomo Diagnostics Pty Ltd., Coherex Medical, Inc. (acquired by Johnson and Johnson Medical NV/SV), Endoscopic Technologies, Inc. d/b/a Estech (acquired by AtriCure, Inc. (NASDAQ: ATRC)) and Vidacare Corporation (acquired by Teleflex Incorporated (NYSE: TFX)). Dr. LaBelle holds M.D. and M.B.A. degrees from Columbia University and a B.S. in Economics from Brigham Young University. We believe that Dr. LaBelle’s extensive experience serving as a venture capitalist and board member to numerous companies in the healthcare industry is valuable to our Company and qualifies him to serve as one of our directors.
image001

Kennetth Lee

Director
Mr. Lee has been a member of our Board of Directors since March 2018. Since January 2003, he has been a general partner of Hatteras Venture Partners, LLC, a venture capital fund focusing on life science companies. Previously he was president of A.M. Pappas & Associates, LLC, following 29 years with Ernst & Young LLP, where he was most recently managing director of the firm’s health sciences corporate finance group. Previously, Mr. Lee served on the boards of several private and public companies, including Abgenix, Inc. (NASDAQ: ABGX, acquired by Amgen, Inc.), CV Therapeutics Inc. (NASDAQ: CVTX, acquired by Gilead Sciences, Inc. (NASDAQ: GILD)), Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH, acquired by Merck &Co., Inc. NYSE: MRK), Maxygen, Inc. (NASDAQ: MAXY, dissolved) and OSI Pharmaceuticals, Inc. (NASDAQ: OSIP, acquired by Astellas Pharma Inc. (OTC: ALPMY)). Mr. Lee received a B.A. from Lenoir-Rhyne College and an M.B.A. from the University of North Carolina at Chapel Hill. We believe that Mr. Lee’s experience advising biotechnology companies regarding financial and partnering strategies, his extensive background in finance and his experience serving on the boards of biotech companies is valuable to our Company and qualifies him to serve as one of our directors.
Anthony Sun

Anthony Sun, MD

Director
Dr. Sun has been a member of our Board of Directors since March 2018. He is involved with many private biotechnology companies. Dr. Sun was at Aisling Capital, a private equity firm dedicated to life sciences, from September 2002 until May 2015, during which he held multiple positions most recently as partner. Dr. Sun served on the board of Versartis, Inc. (NASDAQ: VSAR) from January 2013 to October 2018 and currently serves on the boards of Immusoft Corporation and Senex Biotechnology. Dr. Sun holds a B.S. in Electrical Engineering from Cornell University, an M.D. from Temple University School of Medicine, an M.B.A. from The Wharton School at the University of Pennsylvania, trained in internal medicine at the Hospital of the University of Pennsylvania and was Board Certified in Internal Medicine. We believe Dr. Sun’s experience investing in and serving as a director for companies in the life sciences industry is valuable to our Company and qualifies him to serve as one of our directors.
Maher

Charles Mather

Director
Mr. Mather has been a member of our Board of Directors since March 2018. Since March 2015, Mr. Mather has been Managing Director, Co-Head of Equity Capital Markets at BTIG, LLC. From December 2009 to February 2015, he was the Head of Private and Alternative Capital and Co-Head of Equity Capital Markets at Janney Montgomery Scott, LLC. Between May 2007 and September 2008, Mr. Mather was the head of the Structured Equity Group at Jefferies Group Inc. Prior to that, Mr. Mather held various senior investment banking positions at Cowen and Company, including as Co-Head of the Private Equity Group. Mr. Mather serves on the board Wentz LLC. Mr. Mather also served on the board of Tonix Pharmaceuticals Holdings Corp. (NASDAQ: TNXP) until February 2019 and Finance Company of Pennsylvania (OTC: FCPA) until August 2017. Mr. Mather received a B.A. in History from Brown University and an M.B.A. in Finance from The Wharton School at the University of Pennsylvania. We believe Mr. Mather’s extensive experience advising life science companies as an investment banker is valuable to our Company and qualifies him to serve as one of our directors.
ErnestV3

Ernest Mario, PHD

Director
Dr. Mario has been a member of our Board of Directors since December 2014. Since April 2014, Dr. Mario has served as chairman of Soleno Therapeutics, Inc. ((NASDAQ: SLNO), formerly Capnia, Inc.), a specialty pharmaceutical company in Palo Alto, CA. Dr. Mario joined Pappas Ventures as a member of their Scientific Advisory Board in September 2002 and has been a venture partner since December 2011. Between August 2007 and February 2014, Dr. Mario served as the chief executive officer and chairman of Soleno Therapeutics, and between February 2014 and April 2014, Dr. Mario served as executive chairman. From April 2003 to August 2007, he was chairman and chief executive officer of Reliant Pharmaceuticals, Inc., a privately held pharmaceutical company (acquired by GlaxoSmithKline (NYSE: GSK)). Dr. Mario is currently a director of Soleno Therapeutics (since February 2013), Kindred Biosciences, Inc. (NASDAQ: KIN), Celgene Corporation (since August 2007) (NASDAQ: CELG), Delpor Inc., TAXIS Pharmaceuticals, Inc., Silver Bullet Therapeutics, Inc., and Orbus Therapeutics, Inc. Dr. Mario previously served as a director of Boston Scientific Corporation (NYSE: BSX), VIVUS, Inc. (NASDAQ: VVUS), XenoPort, Inc. (NASDAQ: XNPT, until its acquisition by Arbor Pharmaceuticals, LLC), Maxygen Inc. (NASDAQ: MAXY), Chimerix, Inc. (NASDAQ: CMRX), and TONIX Pharmaceuticals Holding Corp. (NASDAQ: TNXP). Dr. Mario was the deputy chairman and chief executive officer of Glaxo Holdings plc from May 1989 to March 1993 and chairman and chief executive officer of ALZA Corporation from November 1997 to December 2001 and chief executive officer from August 1993 to November 1997. He serves as an advisor to The Ernest Mario School of Pharmacy at Rutgers University. In 2007, Dr. Mario was awarded the Remington Medal by the American Pharmacists’ Association, pharmacy’s highest honor. Dr. Mario received a Ph.D. and an M.S. in physical sciences from the University of Rhode Island and a B.S. in pharmacy from Rutgers University. We believe that Dr. Mario’s significant executive leadership experience, including his experience leading several pharmaceutical companies and extensive experience in financial and operations management, risk oversight, and quality and business strategy is valuable to our Company and qualifies him to serve as one of our directors.
Scientific Advisory Board
Dr. Fredrick

Douglas Fredrick, MD

Clinical Professor and
Board-Certified Ophthalmologist
Dr.Fredrick is a Clinical Professor and board-certified ophthalmologist specializing in pediatric ophthalmology and brings more than 30 years of experience at leading medical institutions. He serves as the Director of Residency Program, Vice Chair of Education and Vice Chair of Clinical Affairs at the Stanford University School of Medicine Byers Eye Institute. Prior to joining Stanford University, he was a full-time faculty member at the University of California San Francisco and Dartmouth
PamGallin

Pamela Gallin, MD

Director Emeritus, Pediatric Ophthalmology
Pamela F. Gallin, M.D., F.A.C.S. is one of the highest ranking female surgeons at NY Presbyterian where she is a Director Emeritus, Pediatric Ophthalmology and Adult Strabismus & Clinical Professor of Ophthalmology in Pediatrics NY Presbyterian-Columbia University Medical Center. She is the author of “Pediatric Ophthalmology”, a textbook used internationally. Dr. Gallin graduated from Washington University in St. Louis MD (Top 10%),
Dr Lin

Shan Lin, MD

Professor of Clinical
Ophthalmology
Shan Lin is Professor of Clinical Ophthalmology at the University of California, San Francisco, and Director of the Glaucoma Service at UCSF and the Zuckerberg San Francisco General Hospital. His research interests include: 1) angle closure glaucoma; 2) glaucoma among Asians; 3) cyclodestructive procedures, and 4) the role of cataract surgery in glaucoma treatment. His leadership positions include Executive Vice President of the World Glaucoma Association, Chair of the Ambassador Committee for the American Glaucoma Society,
Louis_R_Pasquale

Louis R. Pasquale, MD

Professor of Ophthalmology
and Distinguished Scholar
Louis R. Pasquale, MD is Professor of Ophthalmology and Distinguished Scholar in Ophthalmology at Harvard Medical School. In addition to co-directing Harvard’s Glaucoma Center of Excellence, he directs the Glaucoma Service, Glaucoma Fellowship Program and the Teleretinal Program at Massachusetts Eye and Ear Infirmary.
Dt tsai

James C. Tsai, MD

Professor and Chair of Ophthalmology
Dr. James Tsai is the President of New York Eye and Ear Infirmary of Mount Sinai, America’s first and longest operating specialty hospital. He also serves as the Delafield-Rodgers Professor of Ophthalmology at the Icahn School of Medicine at Mount Sinai and System Chair of Ophthalmology for the Mount Sinai Health System. A clinician-scientist and experienced health care administrator,
robert_weintraub

Robert N. Weinreb, MD

Professor and Chair of Ophthalmology
Robert N. Weinreb, MD, is the Distinguished Professor and Chair of Ophthalmology at the University of California, San Diego. He is also Director of the Shiley Eye Institute, Director of the Hamilton Glaucoma Center, holder of the Morris Gleich, MD Chair of Glaucoma and is appointed as Distinguished Professor of Bioengineering. Glaucoma patients from throughout the world are referred to Dr. Weinreb for his medical and surgical expertise.
Close Menu